Objectives
The objective of the study was to determine the incidence of NEC in
pediatric cancer patients receiving chemotherapy in age group 6 months
to 18 years. The other objectives were to assess the clinical and
microbiological profile, outcome and its predictors. We also planned to
evaluate the presence of gut dysbiosis and its significance and role of
fecal calprotectin as a biomarker in NEC.